BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening

Share Article

BellBrook Labs is partnering with the Lankenau Institute for Medical Research to provide sales and marketing support for their innovative Orthogonal Pooled Screening (OPS) Platform, which provides drug discovery researchers with a dramatic increase in efficiency in their efforts to discover new lead molecules. The OPS Platform will allow investigators in academic and startup laboratories to perform high throughput screening (HTS) without investing in the extensive infrastructure required to support management of a large compound library.

BellBrook Labs announced today that they will provide sales and marketing support for the powerful Orthogonal Pooled Screening (OPS) Platform developed and housed at the Chemical Genomics Center at the Lankenau Institute for Medical Research (LCGC) in Wynnewood, Pennsylvania. LCGC’s mission is to measurably improve successful drug discovery outcomes using far more efficient approaches to HTS, by offering rare, drug-like libraries available nowhere else, coupled to a state-of-the-art compound management infrastructure and powerful data mining software. The OPS™ Platform offers startup, academic, government, and foundation laboratories a drastically more efficient and less expensive approach for rapidly finding new leads from a chemically diverse, rare small-molecule collection of more than 100,000 compounds. BellBrook will leverage the distribution channels and customer relationships established with their Transcreener® HTS assays to provide academic and biotech laboratories access to the OPS Platform.

The OPS Platform removes a major barrier for small molecule drug discovery for researchers who do not have ready access to automated HTS equipment or compound libraries. LCGC will provide custom dispensed “assay-ready” plates containing 10 compounds per well, with each compound in duplicate, for a net 5-fold decrease in the number of wells required for screening. For example, a researcher can perform a pilot screen of 8,000 compounds in only five 384-well plates, which can easily be accomplished using manual dispensing and plate-reading equipment. LCGC then uses their proprietary data mining software to identify hits based on the researcher’s cut-off criteria and provides cherry-picked compounds for dose response and secondary assays. The LCGC library of more than 100,000 compounds has been pre-filtered with Lipinski's rules and to remove undesirable features that are not drug-like. The library has a lead-like bias toward low molecular weight compounds. The OPS™ Platform is compatible with a wide variety of cell-based and biochemical assay formats, including BellBrook’s Transcreener® HTS assays.

About BellBrook Labs. BellBrook Labs is dedicated to accelerating drug discovery and biological research by providing innovative high throughput screening solutions for enzymes and phenotypic assays. The company’s Transcreener® HTS enzyme assays, used by all of the major pharmaceutical companies, make it easy to screen thousands of different enzymes, including validated targets like kinases, as well as emerging targets like ATPases, GTPases, methyltransferases, and glycosyltransferases. The iuvo™ Microconduit Array technology and assay screening service is a line of unique microscale devices for miniaturization and automation of advanced cell models that are more representative of human physiology.

The Lankenau Institute for Medical Research was founded in 1927 and is an independent not-for-profit institution engaged in biomedical research. It is affiliated with Main Line Hospitals Inc., a not-for-profit hospital network that is one of the largest in Pennsylvania. The LIMR mission is to advance human health and well-being through research to improve the detection and treatment of disease and the rapid transfer of new technology to the clinic.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Bob Lowery
BellBrook Labs
+1 (608) 227-4501
Email >